# A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

> **NCT00281541** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 29 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** YM155

## Key facts

- **NCT ID:** NCT00281541
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281541, "A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00281541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*